Arthritis Research & Therapy (Jun 2020)
Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan
Abstract
An amendment to this paper has been published and can be accessed via the original article.
